Analysis | Metabolite Name | Measured Value | Units | Gender | Glycemic status | Neuropathy |
---|---|---|---|---|---|---|
Reversed phase NEGATIVE ION MODE | PHENYLALANINE (M-H)- | 47272 | Peak area normalized | female | diabetic | Neuropathy |
Reversed phase NEGATIVE ION MODE | PHENYLALANINE (M-H)- | 251646 | Peak area normalized | female | diabetic | Neuropathy |
Reversed phase NEGATIVE ION MODE | PHENYLALANINE (M-H)- | 293989 | Peak area normalized | female | diabetic | no neuropathy |
Reversed phase NEGATIVE ION MODE | PHENYLALANINE (M-H)- | 335078 | Peak area normalized | female | diabetic | Neuropathy |
Reversed phase NEGATIVE ION MODE | PHENYLALANINE (M-H)- | 346564 | Peak area normalized | female | diabetic | Neuropathy |
Reversed phase NEGATIVE ION MODE | PHENYLALANINE (M-H)- | 348554 | Peak area normalized | female | normoglycemic | no neuropathy |
Reversed phase NEGATIVE ION MODE | PHENYLALANINE (M-H)- | 414414 | Peak area normalized | male | diabetic | no neuropathy |
Reversed phase NEGATIVE ION MODE | PHENYLALANINE (M-H)- | 458618 | Peak area normalized | male | diabetic | Neuropathy |
Reversed phase NEGATIVE ION MODE | PHENYLALANINE (M-H)- | 459906 | Peak area normalized | female | diabetic | no neuropathy |
Reversed phase NEGATIVE ION MODE | PHENYLALANINE (M-H)- | 538395 | Peak area normalized | female | normoglycemic | Neuropathy |
Reversed phase NEGATIVE ION MODE | PHENYLALANINE (M-H)- | 546238 | Peak area normalized | female | diabetic | no neuropathy |
Reversed phase NEGATIVE ION MODE | PHENYLALANINE (M-H)- | 609374 | Peak area normalized | male | pre-diabetic | Neuropathy |
Reversed phase NEGATIVE ION MODE | PHENYLALANINE (M-H)- | 640282 | Peak area normalized | female | diabetic | no neuropathy |
Reversed phase NEGATIVE ION MODE | PHENYLALANINE (M-H)- | 692295 | Peak area normalized | male | pre-diabetic | no neuropathy |